Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prostaglandin composition for the treatment of erectile dysfunction

A technology for erectile dysfunction and composition, which is applied in the field of compositions for treating erectile dysfunction, and can solve problems such as the degree of swelling that cannot be reached

Inactive Publication Date: 2005-04-27
NEXMED HLDG INC
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Penile implants can achieve firmness but not enough swelling

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prostaglandin composition for the treatment of erectile dysfunction
  • Prostaglandin composition for the treatment of erectile dysfunction
  • Prostaglandin composition for the treatment of erectile dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] composition example

[0126] Exemplary Composition A was prepared as follows. by dissolving 0.4 parts prostaglandin E in 5 parts ethanol 1 (Alprostadil USP) to obtain part A. Then, mix 5 parts of dodecyl-(N,N-dimethylamino)-propionate into alcohol-prostaglandin E 1 solution, followed by adding 5 parts of ethyl laurate.

[0127] Part B begins by preparing the water / buffer at pH 5.5. Water / buffer was prepared by adding sufficient potassium monohydrogen phosphate to pure water to obtain a 0.1M solution. The pH of the water / buffer was adjusted to 5.5 with strong base (1N sodium hydroxide) and strong acid (1N phosphoric acid). Buffer is about 80 parts of the total composition. All parts are by weight.

[0128] Add 0.5 parts of ethyl laurate to the buffer. Then, locust bean gum (in powder form) was dispersed in the buffer and homogenized with a stirring device. Table 1 is a list of ingredients. The resulting composition is an easy-to-apply semi-solid for application...

Embodiment 2

[0141] Example Compositions for Healthy Volunteers

[0142]A semisolid prostaglandin composition, Composition H, was administered to healthy volunteers in accordance with the methods of the present invention. It was found that a composition containing an amount of a semisolid prostaglandin component placed in the scaphoid fossa resulted in increased blood flow to the glans and promoted penile swelling. In a preferred embodiment, use by healthy individuals results in swelling of the glans, preferably penile erection. The study was conducted on 8 healthy volunteers without erectile dysfunction.

[0143] Table 2 summarizes some properties related to the study group. Eight healthy volunteers without ED were aged from 27 to 64 years (41.1±11.9, mean±standard deviation). Table 2 gives additional treatment outcome information for each healthy volunteer.

[0144] Evaluation of treatment is based on individual condition evaluation. Briefly, when the composition is administered, ba...

Embodiment 3

[0163] EXAMPLE COMPOSITIONS FOR ED PATIENTS

[0164] A semisolid prostaglandin composition, Composition H, was used in the treatment of ED in a group of patients using the method of the present invention. Placement of a composition comprising an amount of a semi-solid prostate component in the scaphoid fossa results in increased blood flow to the glans and promotes penile swelling. In preferred embodiments, the treatment results in swelling, preferably an erection. The study was performed on 13 ED patients.

[0165] The relevant characteristics of the studied groups are summarized in Table 3. Thirteen ED patients aged 33 to 68 years (51.0±10.3, mean±standard deviation) were screened and treated with an oral dose of 50 mg of sildenafil citrate (Viagra TM ) to achieve a full erection. The severity of erectile dysfunction is evaluated by the 5-item International Index of Erectile Function (IIEF-5). A low score of 5-item questionnaire within 0-25 indicates severe erectile dysf...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for the treatment of erectile dysfunction are provided comprising placing in the fossa navicularis an amount of a semi-solid vasoactive prostaglandin composition sufficient to increase blood flow in the glans penis and resulting in increased tumescence of the penis. In preferred embodiments, the method further comprises providing erotic stimuli. Another embodiment, the invention provides a method for increasing the tumescence of the glans penis. In another aspect, the invention provides compositions and articles of manufacture for the practice of the methods of the invention.

Description

[0001] Related references [0002] This application claims priority to US Provisional Application 60 / 357,282, filed February 15,2002. [0003] The entire contents of the above application are hereby fully incorporated by reference. [0004] technical field of invention [0005] The present invention relates to a composition and a method for treating erectile dysfunction, in particular to a pharmaceutical composition and a method for increasing the microcirculation of the glans penis and promoting the swelling of the glans penis by administration at the patient's fossa navicularis. Background of the invention [0006] Previous treatments for impotence and erectile dysfunction (ED) have focused on achieving an erection sufficient for sexual intercourse, especially the ability to enter the vagina. While much progress has been made in the field, the problem of erections still not being sufficient to satisfy the patient or his sexual partner remains. [0007] The term "impotence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/10A61K9/00A61K9/06A61K31/165A61K31/498A61K31/505A61K31/517A61K31/557A61K31/5575A61K45/00A61K47/14A61K47/32A61K47/36A61P15/10
CPCA61K31/165A61K31/505A61K31/498A61K9/0014A61K9/06A61K9/0034A61K47/36A61K47/32A61K31/557A61P15/10A61K47/14
Inventor 冈田耕市詹姆斯·L·亚格那迪·布亚迪金瑟维特·布亚迪金
Owner NEXMED HLDG INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com